In Vitro Toxicology Testing Market

The global in vitro toxicology testing market in terms of revenue was estimated to be worth $10.8 billion in 2023 and is poised to reach $17.1 billion by 2028, growing at a CAGR of 9.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of in vitro toxicology testing market is largely driven by the emergence of promising new toxicology testing technologies, and increased research and development investment for early toxicity detection. Furthermore, due to the ban on animal testing, the in vitro toxicology testing industry has seen substantial expansion over the last decade.

In Vitro Toxicology Testing Market Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the In Vitro Toxicology Testing Market

In Vitro Toxicology Testing Market Dynamics

DRIVER: Growing public resistance against animal testing

The increasing resistance of the public towards animal testing has been a significant driving force for the growth of the in vitro toxicology testing market. This shift in public sentiment is driven by various factors, including ethical concerns, awareness of animal rights, and a growing understanding of the limitations and ethical dilemmas associated with traditional animal testing methods. As a result, there has been a notable impetus to find alternative approaches to assess the safety and toxicity of products and substances without relying on animal experimentation. Animal testing is a highly time-consuming process and involves high costs and immense safety risks for the animals involved. Working with rodent and rabbit models also increases the risk of zoonotic diseases. The European Animal Research Association, 7th Amendment to EU Directive 76/768/EEC, passed in 2003, introduced a gradual prohibition on animal testing for cosmetics, culminating in a deadline of 2013. On March 11, 2013, the complete ban took effect, making it unlawful to market or sell cosmetics within the EU if either the finished product or its constituent ingredients had undergone testing on animals.

RESTRAINT: Failure to establish intricacies of in vivo conditions

With regulatory authorities introducing bans on animal testing in several countries for testing drugs or substances with potential hazards, in vitro toxicity testing is gaining wide recognition. However, compared to in vivo tests, in vitro toxicology testing methods still need to demonstrate their validity. In vitro tests can determine only the mechanism of action of test substances and not their outcomes after being metabolized. A chemical substance may not be harmful, but its metabolites can prove to be detrimental. One such example is a polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene, a metabolite of a chemical that is mutagenic and carcinogenic. In vivo methods are still practiced in the pharmaceuticals, food, and chemical industries to ensure the safety of substances. Research in the workings of in vivo environments is still lacking; as a result, while efforts are being made to develop in vitro techniques to simulate in vivo conditions, there are no tangible results yet. Hence, the use of in vivo methods is the major restraint of this market.

OPPORTUNITY: Increasing focus on predictive toxicology

Predictive toxicology relies on structure-activity relationship (SAR) modeling to predict biological activities in chemical structures. Such approaches have proven capabilities when applied to well-defined toxicity endpoints or regions of chemical space. Computational approaches continue to increase in capability and applicability to predictive toxicology. These advanced methodologies are utilized in various stages of the development of substances by predicting properties that correlate with toxicity endpoints, structure-activity relationship models for new chemical formulations, and building/retrieving information on chemical databases. In the field of drug design, one primary need is the early recognition of potentially toxic molecules. In fact, attrition due to nonclinical safety represents a major issue for the productivity of pharmaceutical R&D. To this end, the development of predictive toxicology assays and models has become a primary concern for drugmakers.

CHALLENGE: Complexity in data analysis and management

Complexity in data analysis and management has emerged as a major limitation to the growth of the in vitro toxicology testing market. One key factor is the sheer volume of data generated during in vitro toxicology experiments. With the advent of high-throughput screening technologies, researchers can assess thousands of compounds simultaneously, leading to massive datasets. Managing and analyzing this data requires advanced computational tools and expertise, which can be expensive and timeconsuming to develop and maintain. For example, a pharmaceutical company conducting toxicity screening for a new drug candidate may generate terabytes of data from various assays, making it challenging to extract meaningful insights efficiently. Moreover, the diversity of data types in in vitro toxicology adds to the complexity. Researchers integrate information from genomics, proteomics, metabolomics, and other omics disciplines to gain a comprehensive understanding of toxicity mechanisms. This multidimensional data landscape demands sophisticated data integration and analysis approaches, which can be a barrier for smaller companies and research institutes with limited resources.

Global In Vitro Toxicology Testing Market Ecosystem Analysis

The ecosystem of in vitro toxicology testing consists of end users from pharmaceutical & biotechnology companies, consumer care companies, food industry, chemical industry, and academic & research institutes, in vitro toxicology testing product and service providers, instrument & reagent suppliers, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of in vitro toxicology testing products and services, enhance drug discovery processes, and develop new therapeutics.

Cellular assays held a dominant share in the method segment in the in vitro toxicology testing industry

Based on the method, the in vitro toxicology testing market has been segmented into cellular assays, biochemical assays, molecular toxicology assays, ex vivo models, and in silico models. In 2022, cellular assays accounted for the largest share of the in vitro toxicology testing market. This is attributed to the high adoption of these assays across all industries due to their higher speed, higher efficiency, and lower cost than other methods.

The toxicogenomics segment of the in vitro toxicology testing industry is expected to register fastest growth during the forecast period.

Based on the technologies used in in vitro toxicology testing, the market has been segmented into cell culture, high-throughput screening, and toxicogenomics. In 2022, cell culture technologies accounted for the largest share. The cell culture technology segment's dominance is due to its status as the preferred method for toxicity testing because of its ability to replicate in vivo conditions. Nonetheless, it is anticipated that the toxicogenomics segment will achieve the highest CAGR during the projected period. The advancement of technology in proteomics and genomics is predicted to support the expansion of this segment.

To know about the assumptions considered for the study, download the pdf brochure

Europe accounted for the largest share in In vitro toxicology testing industry in 2022

Geographically, the In vitro toxicology testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe held the dominant share followed by North America. The European Union has been a leader in supporting research for the development and validation of advanced in vitro toxicology testing protocols for regulatory purposes. Thus, the development of newer drugs and personal care products, R&D efforts by EU states to bring in alternatives to animal testing, and a ban on animal-tested cosmetics are contributing to the growth of the European in vitro toxicology testing market.

Key players in the global In vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US).

Scope of the In Vitro Toxicology Testing Industry:

This report categorizes the In vitro toxicology testing market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Consumables
• Assays
• Bacterial Toxicity Assays
• Enzyme Toxicity Assays
• Cell-Based Elisa and Western Blots
• Receptor-Binding Assays
• Tissue Culture Assays
• Other Assays
• Services
• Equipment
• Software

By Toxicity Endpoint & Test

• ADME
• Genotoxicity
• Skin irritation, Corrosion & Sensitization
• Cytotoxicity
• Ocular Toxicity
• Organ Toxicity
• Dermal Toxicity
• Phototoxicity
• Other End Point & Tests

By Industry

• Pharmaceutical & Biopharmaceutical
• Consumer Care
• Food
• Others

By Technology

• Cell Culture
• High-throughput
• Toxicogenomics

By Method

• Cellular Assays
• Biochemical Assays
• Molecular Toxicology Assays
• Ex-vivo Models
• In Silico Models

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East & Africa
  • Middle East
  • Africa

Recent Developments of In Vitro Toxicology Testing Industry

• In March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion’s ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.
• In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst